In case you missed this interesting announcement last week:
Tulane University School of Medicine participates in pilot program
INDIANAPOLIS, Feb. 12, 2014 /PRNewswire/ -- Lilly USA, LLC (NYSE: LLY) announced today the launch of a new rotation program for aspiring physicians. The rotation assignments cut across different aspects of the pharmaceutical company's business - from drug discovery and development to bioethics and patient safety - providing third- and fourth-year medical students a lens into the pharmaceutical industry, its vision and focus on improving patient outcomes.
Students from Tulane University School of Medicine will be the first to participate in the pilot program at Eli Lilly and Company's Indianapolis headquarters.
Showing posts with label Eli Lilly. Show all posts
Showing posts with label Eli Lilly. Show all posts
Wednesday, February 19, 2014
Monday, July 19, 2010
Eli Lilly Cutting 340 Jobs in Indiana
The Indianapolis Start reported last Friday that Lilly will be cutting 340 information technology jobs in Indiana. They will probably cut another 170 manufacturing jobs by the end of 2010, and most of those jobs will be in Indiana as well.
In fact, Lilly will be cutting approximately 5,500 jobs by the end of 2011. So far, Lilly has announced 2,000 job cuts, so they're almost half-way there. Lilly currently employs 12,400 people in Indiana. The population of Indianapolis is 6,423,113, so Lilly employs 0.2% of the population of Indiana. That's a fairly significant impact in a single state.
Why all these job cuts in the pharmaceutical industry? Are these the effects of the global recession, or is there something more specific that's happening within the biopharma industry? Over the next 3 years, Lilly will lose patents on four of its bestselling drugs, so that's going to have a considerable impact on its $22 billion annual revenue.
In fact, Lilly will be cutting approximately 5,500 jobs by the end of 2011. So far, Lilly has announced 2,000 job cuts, so they're almost half-way there. Lilly currently employs 12,400 people in Indiana. The population of Indianapolis is 6,423,113, so Lilly employs 0.2% of the population of Indiana. That's a fairly significant impact in a single state.
Why all these job cuts in the pharmaceutical industry? Are these the effects of the global recession, or is there something more specific that's happening within the biopharma industry? Over the next 3 years, Lilly will lose patents on four of its bestselling drugs, so that's going to have a considerable impact on its $22 billion annual revenue.
Monday, February 23, 2009
The European Commission Approves Efient (prasugrel
No, not Effient (which is the proposed US tradename). Efient (prasugrel) has been approved in Europe for acute coronary syndrome (ACS) patients undergoing PCI. The annoucement was made by Daiichi Sankyo Company, Limited and Eli Lilly and Company.
Two of the major prasugrel studies are:
Two of the major prasugrel studies are:
- TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction), and
- TRILOGY ACS (TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes),
Wednesday, February 11, 2009
Deirdre Connelly Leaves Eli Lilly for GSK
Lot's of movement in pharma. One of the most recent headlines:
Deirdre Connelly Leaves Eli Lilly for GSK
What do you think about that? Deirdre Connelly was named one of the 50 most powerful women by Fortune Magazine. In 2007, her rank was 47. In 2008, her rank moved to 42. What will it be for 2009?
Deirdre Connelly Leaves Eli Lilly for GSK
What do you think about that? Deirdre Connelly was named one of the 50 most powerful women by Fortune Magazine. In 2007, her rank was 47. In 2008, her rank moved to 42. What will it be for 2009?
Subscribe to:
Posts (Atom)